俄亥俄州药物委员会羟氯喹禁令激民愤 昨日宣布放弃执行

3
1398

新闻简述:俄亥俄州药物委员会此前禁止使用氯喹和羟氯喹治疗CCP新冠病毒的公告遭到医护人员和患者群体抗议,迫于压力和州长的明确要求下,该协会于7月30日宣布撤销该规定及相关条例。

Requirements for Dispensing or Selling Chloroquine and Hydroxychloroquine in Ohio

关于羟氯喹在俄亥俄州的出药和销售要求

Updated 7/30/2020

更新于7/30/2020

As a result of the feedback received by the medical and patient community and at the request of Governor DeWine, the State of Ohio Board of Pharmacy has withdrawn proposed rule 4729:5-5-21 of the Administrative Code. Therefore, prohibitions on the prescribing of chloroquine and hydroxychloroquine in Ohio for the treatment of COVID-19 will not take effect at this time. This will allow the Board to reexamine the issue with the assistance of the State Medical Board of Ohio, clinical experts, and other stakeholders to determine appropriate next steps. Licensees should be aware that emergency rule 4729-5-30.2 is no longer effective and the requirements of that rule, including the inclusion of a diagnosis code on any prescription for chloroquine and hydroxychloroquine, are no longer applicable

鉴于来自医护人员和相关患者的反馈 ,并应州长DeWine的要求,俄亥俄州医药协会特此撤回拟议条例4729:5-5-21 。由此,禁止在俄亥俄州开处方氯喹和羟氯喹用于治疗COVID-19 的规定即日起失效。协会将在俄亥俄州医学委员会,临床专家及相关机构和人员的协助下重新审查该条例并确定适当的后续步骤。具医疗资质人员请注意,紧急条例4729-5-30.2不再有效,其规定在任何氯喹和羟基氯喹的处方上注明诊断代码将不再适用。

阅读英文公告原文

【附录:俄亥俄州长DeWine敦促俄亥俄州药物委员会终止羟氯喹禁令的推特截图】

附录:俄亥俄州药物委员会此前发布的限制使用羟氯喹的公告

4729:5-5-21 Prescription requirements for chloroquine and hydroxychloroquine. 

4729:5-5-21氯喹和羟氯喹的处方要求

(A) No prescription for chloroquine or hydroxychloroquine may be dispensed by a pharmacist or sold at retail by a licensed terminal distributor of dangerous drugs, including prescriptions for patients residing in Ohio dispensed or sold at retail by nonresident terminal distributors of dangerous drugs as defined in rule 4729:5-8-01 of the Administrative Code, unless the prescription bears a written diagnosis code from the prescriber or a statement indicating its veterinary medical purpose. 

(A)氯喹或羟氯喹的处方药将不允许通过药剂师配给或在有危险药品特许销售资质的零售点出售,包括配给俄亥俄州本地居民的或由有危险药品特许销售资质的非本地零售点出售的符合第4729:5-8-01号条例定义的处方药。除非处方上开处方者的书面诊断代码或声明为兽医用。

(B) Except as provided in paragraph (C) of this rule, prescriptions issued for chloroquine or hydroxychloroquine for prophylactic use related to COVID-19 or for the treatment of COVID-19 are strictly prohibited unless otherwise approved by the board’s executive director in consultation with the board president, at which time a resolution shall issue. Upon the effective date of this rule, all previous approvals for the use of chloroquine or hydroxychloroquine shall be deemed void and must be approved using the process outlined in this paragraph. 

(B)除非如条款(C)另有规定,严格禁止开具氯喹或羟氯喹作为预防或治疗COVID-19相关治疗的处方药,除非经由经董事会执行董事与董事会主席协商同意,届时将正式决议。在本规定生效后,在此之前所有使用氯喹或羟氯喹的批准均应视为无效,必须按照本条款规定程序进行审批。

(C) The prohibition in paragraph (B) of this rule does not apply to prescriptions issued as part of a documented institutional review board-approved clinical trial to evaluate the safety and efficacy of the drugs to treat COVID-19. Prescriptions must include documentation that the patient is enrolled in a clinical trial. 

(C)条款(B)中的禁令不适用于已获得机构审查委员会批准的临床试验的处方,该处方用于评估治疗COVID-19的药物的安全性和有效性。处方必须包括有关该患者已参加临床试验的文件。

(D) Paragraphs (B) and (C) of this rule shall also apply to medication orders and outpatient prescriptions dispensed by institutional pharmacies as defined in agency 4729 of the Administrative Code

4729:5-5-21 2 

(D)条款(B)和(C)也应适用于代理条例第4729条所定义的公共药房配给的药品订单和门诊处方药

4729:5-5-21 2

Replaces: 4729-5-30.2 

替代:4729-5-30.2

Effective: 7/30/2020

生效日期:2020年7月30日

Five Year Review (FYR) Dates: 07/30/2025

五年审查(FYR)日期:07/30/2025

CERTIFIED ELECTRONICALLY Certification 

07/20/2020 

电子认证日期

07/20/2020 

Date Promulgated Under: 119.03 

颁布日期:119.03

Statutory Authority: 4729.26, 3719.28

法定机构:4729.26,3719.28

 Rule Amplifies: 4729.26, 4729.54, 4729.55 

细则:4722.96、4725.94、4729.55

Prior Effective Dates: 03/22/2020 (Emer.)

先前生效日期:03/22/2020(Emer。)

阅读此公告英文原文

翻译:【一花一世界】编辑整理:【Isaiah4031】

战友之家玫瑰园小队出品

4
3 评论
Inline Feedbacks
View all comments
joop12345
1 天 之前

0
maliya
2 天 之前

羟氯喹在俄亥俄州终于解禁!

0